Replimune Reports $69.8 Million Net Loss, Progresses with TUDRIQEV Launch

Replimune Group, Inc. reported a net loss of $69.8 million for the three months ended June 30, 2026, a decrease from the $86.7 million loss recorded in the same period the previous year. The company's total operating expenses for the quarter were $68.2 million, down from $90.4 million in the prior year, primarily due to reduced research and development costs, which fell to $49.3 million from $57.8 million. Selling, general, and administrative expenses also decreased significantly, from $32.6 million to $19.0 million, reflecting a restructuring effort that included a workforce reduction of approximately 55%.

In terms of financial position, Replimune's total assets decreased to $252.4 million as of June 30, 2026, down from $332.4 million at the end of the previous fiscal quarter. The decline in assets was driven by a reduction in cash and cash equivalents, which fell to $185.4 million from $209.0 million. The company’s accumulated deficit increased to $1.33 billion, reflecting ongoing investment in its product development pipeline, which includes TUDRIQEV, an oncolytic immunotherapy recently granted accelerated approval by the FDA for treating advanced melanoma.

Strategically, Replimune has made significant progress with the commercialization of TUDRIQEV, which is now in the launch phase following its FDA approval on August 6, 2026. The company is also conducting confirmatory trials, including the ongoing IGNYTE-3 trial, which is a post-marketing requirement. The approval of TUDRIQEV is a pivotal milestone for Replimune, as it marks the first product in its pipeline to receive regulatory clearance, potentially opening new revenue streams.

Operationally, Replimune has focused on enhancing its clinical trial capabilities and expanding its product pipeline. The company is advancing its other product candidates, RP2 and RP3, which are designed to enhance anti-tumor immune responses. As of June 30, 2026, Replimune had cash and cash equivalents and short-term investments totaling $195.3 million, which the company believes will be sufficient to fund operations for more than twelve months, including the commercialization of TUDRIQEV.

Looking ahead, Replimune anticipates continued operating losses as it invests in the commercialization of TUDRIQEV and the development of its other product candidates. The company will need to secure additional funding to support its operations and growth initiatives, as it has not yet generated revenue from product sales. The successful launch of TUDRIQEV and the outcomes of ongoing clinical trials will be critical in determining the company's future financial performance and market position.